PRIOR AUTHORIZATION POLICY

POLICY: Oncology – Ibrance® (palbociclib capsules and tablets – Pfizer Labs)

DATE REVIEWED: 04/15/2020

OVERVIEW

Ibrance, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is indicated for the treatment of adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:

1. An aromatase inhibitor (AI) as initial endocrine-based therapy in postmenopausal women or in men[1-3]; or
2. Fulvestrant in patients with disease progression following endocrine therapy.[1,4-5]

Disease Overview

Based on molecular profiling, breast cancer is classified as HR+ (estrogen receptor positive [ER+] and/or progesterone receptor positive [PgR+]), HER2+, or triple negative (ER-negative, PgR-negative, and HER2-negative).[6-7] Most breast cancers in women (71%) are HR+, HER2-negative; these cancers tend to be slow-growing and less aggressive than other subtypes.[7] HR+, HER2-negative tumors are associated with the most favorable prognosis compared with other subtypes, particularly in the short-term, in part because expression of hormone receptors is predictive of a favorable response to hormonal therapy. In men, about 85% of breast cancers are ER+ and 70% are PgR+.[8] About 12% of breast cancers are HR+ and HER2+, and tend to be higher grade and more aggressive than HR+ cancers.[7] About 5% of breast cancers are HER2+ and do not express hormone receptors. These cancers tend to be more aggressive than other breast cancers and have a poorer short-term prognosis compared with ER+ breast cancers. About 12% of breast cancers in women are triple negative and have a poorer short-term prognosis than other subtypes.

Guidelines

The National Comprehensive Cancer Network (NCCN) guidelines on breast cancer (version 3.2020 – March 6, 2020) recommend any of the CDK4/6 inhibitors in combination with an AI or fulvestrant as a first-line treatment option for recurrent or Stage IV HR+ and HER2-negative disease in postmenopausal women or premenopausal patient receiving ovarian ablation or suppression (category 1).[9,12] The compendium recommend that men with breast cancer be treated similarly to postmenopausal women, except that the use of an AI is ineffective without concomitant suppression of testicular steroidogenesis.[10] The NCCN guidelines state in a footnote that if there is disease progression on CDK4/6 inhibitor therapy, there are limited data to support an additional line of therapy with another CDK4/6-containing regimen.[9] The limited data are based on a multicenter analysis which evaluated clinical outcomes in patients (n = 58) with HR+/HER2-negative metastatic breast cancer who received Verzenio after disease progression on Ibrance or Kisqali.[13] At data cutoff, 34% of patients (n = 20/58) had progressive disease, while 36% of patients (n = 21/58) had treatment duration exceeding 6 months. The median PFS was 5.8 months. There are no published data with additional line of therapy with Ibrance or Kisqali, if the patient has progressed on Verzenio.

In men with breast cancer, tamoxifen is generally used rather than an AI, because the data supporting use of an AI in men are limited.[8-9] The use of AI therapy with LHRH has been reported. Only limited data are available with Kisqali use in men with breast cancer as first-line endocrine therapy in combination with anastrozole, exemestane, or letrozole or for combination use with fulvestrant. However, available real-world data suggest comparable efficacy and safety profiles in men as in women; it is reasonable to recommend CDK4/6 inhibitors in combination with an aromatase inhibitor or fulvestrant, everolimus, and

PIK3CA inhibitors to men based on extrapolation of data from studies comprised largely of female participants with advanced breast cancer.

The NCCN guidelines on soft tissue sarcoma (version 6.2019 – February 10, 2020) recommend Ibrance as single-agent therapy for the treatment of WD-DDLS for retroperitoneal sarcomas (category 2A).[11]

POLICY STATEMENT

Prior authorization is recommended for prescription benefit coverage of Ibrance. All approvals are provided for 3 years in duration unless otherwise noted below. In the clinical criteria, as appropriate, an asterisk (*) is noted next to the specified gender. In this context, the specified gender is defined as follows: a woman is defined as an individual with the biological traits of a woman, regardless of the individual's gender identity or gender expression; men are defined as individuals with the biological traits of a man, regardless of the individual's gender identity or gender expression.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Ibrance is recommended in those who meet the following criteria:

FDA-Approved Indications

1. **Breast Cancer in Postmenopausal Women***. Approve for 3 years if the patient meets the following criteria (A, B, C, and D):
   - **A)** Patient has advanced or metastatic hormone receptor positive (HR+) [i.e., estrogen receptor positive {ER+} and/or progesterone receptor positive {PR+}] disease; AND
   - **B)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND
   - **C)** The patient meets ONE of the following criteria (i or ii):
     - **i.** Ibrance will be used in combination with anastrozole, exemestane, or letrozole; OR
     - **ii.** Ibrance will be used in combination with fulvestrant; AND
   - **D)** The patient has not had disease progression while on Ibrance, Kisqali (ribociclib tablets), or Verzenio (abemaciclib tablets).

   ***** Refer to the Policy Statement.

2. **Breast Cancer in Pre/Perimenopausal Women***. Approve for 3 years if the patient meets the following criteria (A, B, C, D, and E):
   - **A)** Patient has advanced or metastatic hormone receptor positive (HR+) [i.e., estrogen receptor positive {ER+} and/or progesterone receptor positive {PR+}] disease; AND
   - **B)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND
   - **C)** The patient is receiving ovarian suppression/ablation with a gonadotropin-releasing hormone (GnRH) agonist (e.g., Lupron [leuprolide], Trelstar [triptorelin], Zoladex (goserelin]), or has had surgical bilateral oophorectomy or ovarian irradiation; AND
   - **D)** Patient meets ONE of the following conditions (i or ii):
     - **i.** Ibrance will be used in combination with anastrozole, exemestane, or letrozole; OR
     - **ii.** Ibrance will be used in combination with fulvestrant; AND
   - **E)** Patient has not had disease progression while on Ibrance, Kisqali (ribociclib tablets), or Verzenio (abemaciclib tablets).

***** Refer to the Policy Statement.

3. **Breast Cancer in Men*.** Approve for 3 years if the patient meets the following criteria (A, B, C, and D):
   - **A)** Patient has advanced or metastatic hormone receptor positive (HR+) [i.e., estrogen receptor positive {ER+} and/or progesterone receptor positive {PR+}] disease; AND
   - **B)** Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer; AND
   - **C)** Patient meets ONE of the following criteria (i or ii):
     - **i.** Patient meets BOTH of the following criteria (a and b):
       - **a)** Patient is receiving a gonadotropin-releasing hormone (GnRH) agonist (e.g., Lupron [leuprolide], Trelstar [triptorelin], Zoladex (goserelin]); AND
       - **b)** Ibrance will be used in combination with anastrozole, exemestane, or letrozole; OR
     - **ii.** Ibrance will be used in combination with fulvestrant; AND
   - **D)** Patient has not had disease progression while on Ibrance, Kisqali (ribociclib tablets), or Verzenio (abemaciclib tablets).

***** Refer to the Policy Statement.

Other Uses With Supportive Evidence

4. **Liposarcoma**. Approve for 3 years if the patient has well-differentiated/dedifferentiated liposarcoma (WD-DDLS).

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Ibrance has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below.

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Ibrance® capsules and tablets [prescribing information]. New York, NY: Pfizer Labs; November 2019.
2. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*. 2016;375(20):1925-1936.
3. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. *Lancet Oncol.* 2015;16:25-35.
4. Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med.* 2015;373:209-219.
5. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016;17(4):425-439.
6. National Cancer Institute: PDQ® Breast cancer treatment. National Cancer Institute. Date last modified February 4, 2018 Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq. Accessed on March 2, 2018.
7. American Cancer Society. *Breast Cancer Facts & Figures 2017-2018*. Atlanta: American Cancer Society, Inc. 2017. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf. Accessed on March 2, 2018.
8. National Cancer Institute: PDQ® Male breast cancer treatment. Bethesda, MD: National Cancer Institute. Date last modified February 8, 2018. https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq. Accessed on March 2, 2018.

9. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 3.2020 – March 6, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on April 13, 2020.
10. Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. *J Clin Oncol*. 2016;34(25):3069-3103.
11. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 6.2019 – February 10, 2020) © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on April 13, 2020.
12. The NCCN Drugs & Biologics Compendium. © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on April 13, 2020. Search terms: palbociclib.
13. Wander SA, Zangardi M, Niemierko A, et al. A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone-receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). *J Clin Oncol*. 2019;37:15_suppl, 1057-1057.